AgomAb Therapeutics (NASDAQ:AGMB) Shares Gap Up – Time to Buy?

AgomAb Therapeutics NV (NASDAQ:AGMB)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $12.82, but opened at $13.40. AgomAb Therapeutics shares last traded at $14.16, with a volume of 133,752 shares changing hands.

Analyst Ratings Changes

Several analysts have commented on AGMB shares. Piper Sandler assumed coverage on shares of AgomAb Therapeutics in a report on Tuesday. They set an “overweight” rating and a $60.00 target price on the stock. HC Wainwright assumed coverage on AgomAb Therapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $35.00 price target on the stock. B. Riley Financial assumed coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target for the company. Wall Street Zen cut shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics in a report on Wednesday, August 19th. They issued an “overweight” rating on the stock. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $37.50.

AgomAb Therapeutics Stock Performance

The stock’s 50-day simple moving average is $12.94.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. Equities analysts predict that AgomAb Therapeutics NV will post -1.71 earnings per share for the current fiscal year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.